AbbVie Inc. Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. AbbVie Inc. operates as a single global business segment focused on immunology, neuroscience, oncology, aesthetics, and eye care. The company reported strong revenue growth driven by its immunology portfolio, offset by continued declines in Humira sales due to biosimilar competition.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Revenues | $13,343 | $12,310 |
| Operating Earnings | $3,733 | $2,798 |
| Net Earnings (Attributable to AbbVie) | $1,286 | $1,369 |
| Diluted EPS | $0.72 | $0.77 |
| Cash Flow from Operations | $1,635 | $4,040 |
| Free Cash Flow (Approx.) | $1,400 | $3,847 |
| Total Debt (Current + Long-term) | $69,889 | $67,144 |
| Cash and Equivalents | $5,175 | $5,524 |
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($235M).
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 8.4% year-over-year (10% at constant currency), driven primarily by Skyrizi (+70.5%) and Rinvoq (+57.2%).
- Humira Decline: Humira revenues decreased 50.6% to $1.12 billion, reflecting the ongoing impact of biosimilar competition.
- Operating Expenses: Operating earnings increased significantly to $3.73 billion, despite higher R&D ($2.07B vs $1.94B) and Acquired IPR&D expenses ($248M vs $164M).
- Non-Operating Items: "Other expense, net" increased to $1.44 billion (from $586 million), primarily due to a $1.52 billion charge for the change in fair value of contingent consideration liabilities.
- Cash Flow: Operating cash flow decreased to $1.64 billion from $4.04 billion, attributed to working capital timing and litigation payments.
Guidance, Outlook, and Risks
- Acquisitions & Pipeline: Completed the acquisition of Nimble Therapeutics ($288M) and finalized the valuation for Cerevel Therapeutics. Entered a licensing agreement with Gubra A/S for an obesity treatment (upfront payment of $350M to be expensed in Q2 2025).
- Capital Allocation: Declared a quarterly dividend of $1.64 per share. Repurchased 3 million shares for $606 million; approximately $2.9 billion remains in the repurchase authorization.
- Debt Management: Issued $4.0 billion in new senior notes and repaid $3.0 billion in maturing debt. Entered a new $3.0 billion revolving credit facility.
- Risks: Significant exposure to litigation, including opioid liability (Allergan), breast implant (Biocell) claims, and antitrust matters. The company maintains a litigation accrual of approximately $1.8 billion. Macroeconomic risks include potential tariffs and trade disruptions.
Investor Verification Checklist
- Contingent Consideration Volatility: Verify the sensitivity of the $1.52 billion fair value adjustment to future sales projections and discount rates, as this significantly impacts net earnings.
- Humira Trajectory: Monitor the rate of Humira revenue decline and the corresponding market share gains of Skyrizi and Rinvoq to assess long-term revenue stability.
- Litigation Accruals: Review the $1.8 billion litigation reserve and the status of the opioid and breast implant settlements to gauge potential future cash outflows.
- Debt Service: Assess the impact of the new $4.0 billion debt issuance on future interest expenses and liquidity ratios.
- Working Capital: Investigate the specific drivers behind the $1.48 billion increase in accounts receivable and the timing of litigation payments affecting operating cash flow.